Approaches, Progress, and Challenges to Hepatitis C Vaccine Development

Research output: Contribution to journalArticlepeer-review


Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75 million new cases worldwide in 2015. The World Health Organization aims for a 90% reduction in new HCV infections by 2030. An HCV vaccine would prevent transmission, regardless of risk factors, and significantly reduce the global burden of HCV-associated disease. Barriers to development include virus diversity, limited models for testing vaccines, and our incomplete understanding of protective immune responses. Although highly effective vaccines could prevent infection altogether, immune responses that increase the rate of HCV clearance and prevent chronic infection may be sufficient to reduce disease burden. Adjuvant envelope or core protein and virus-vectored nonstructural antigen vaccines have been tested in healthy volunteers who are not at risk for HCV infection; viral vectors encoding nonstructural proteins are the only vaccine strategy to be tested in at-risk individuals. Despite development challenges, a prophylactic vaccine is necessary for global control of HCV.

Original languageEnglish (US)
Pages (from-to)418-430
Number of pages13
Issue number2
StatePublished - Jan 2019


  • HCV
  • Prophylactic Vaccination
  • Vaccines
  • Viral Hepatitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Approaches, Progress, and Challenges to Hepatitis C Vaccine Development'. Together they form a unique fingerprint.

Cite this